CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

Study acronym: CARLA
StatusUnknown
PhasePhase 1
SponsorFamiCordTx
Started

Record status This record was last updated September 19, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
FamiCordTx
1 trial monitored
See all monitored trials
Leukemia
2,957 trials monitored
See 176 trials at risk
Non-Hodgkin Lymphoma
2,017 trials monitored
See 114 trials at risk
Acute Lymphoblastic Leukemia (ALL)
934 trials monitored
See 55 trials at risk
and 2 more diseases
One arm, open label study to assess the clinical use of Investigational Medicinal Product FCTX-CL19-1 (scientific name: Tarcidomgen Kimleucel) containing autologous anti-CD19 CAR T cells with a preliminary determination of the safety of intravenous IMP administration in patients diagnosed with refractory and relapsed CD19 + B cell neoplasms.
Trial Details
NCT Number NCT06593145
Lead Sponsor FamiCordTx
Conditions
(from sponsor)		 Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL), Large B-cell Lymphoma
Related terms Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov